US Institutional VC Allocation to Israeli Technology

US institutional venture capital allocation to Israel is the single largest non-Israeli capital pool funding the Israeli technology sector. Across the major US-anchored funds — Sequoia, Bessemer, Insight Partners, General Atlantic, Andreessen Horowitz, Tiger Global, Coatue, Battery Ventures, Norwest, and the broader institutional bench — annual Israeli deployment has held in the multi-billion-dollar range across the post-2022 reset cycle.

For Israeli founders, the US institutional capital channel functions as the dominant Series B-and-later financing source. For US LPs, Israeli technology functions as one of the largest international VC allocations outside the United States itself. The corridor is structural, not opportunistic.

The named US funds with deep Israeli activity

Sequoia Capital. Long-running Israel allocation through its US and global funds. Active Israeli portfolio includes positions across cybersecurity, AI infrastructure, and enterprise software. The 2023 firm restructuring — separating Sequoia Capital (US and Europe) from HongShan (China) and Peak XV Partners (India and Southeast Asia) — preserved Israeli activity inside the US-anchored Sequoia Capital entity.

Bessemer Venture Partners. One of the most consistent US-anchored allocators to Israeli technology over a multi-decade horizon. Israeli portfolio companies include and have included Wiz, Pagaya, Fiverr, Habana Labs, and the broader bench. The Israel partnership is institutionalized — not an opportunistic geography.

Insight Partners. Among the largest single deployers of US institutional capital into Israeli growth-stage software companies. Insight's Israel exposure spans hundreds of investments across the 2018-2024 cycle. The post-2022 reset has compressed pace but not strategic positioning.

General Atlantic. Growth-stage focus, with selective but substantial Israeli positioning across fintech, healthcare-IT, and AI-adjacent sectors.

Andreessen Horowitz. More selective than Bessemer or Insight on Israeli activity, but with high-conviction Israeli positions when the firm engages. AI and cybersecurity are the dominant lanes.

Tiger Global, Coatue, and the crossover bench. Heavily active in Israeli growth-stage rounds through 2021. Materially compressed pace through 2022-2024. 2025-2026 activity has returned, but at lower volume and more disciplined valuations.

Battery Ventures and Norwest Venture Partners. Long-standing Israeli activity, more concentrated in software and enterprise infrastructure.

Lightspeed, Accel, and the broader institutional bench. Variable Israeli activity by partner and by cycle, but consistent strategic positioning.

The LP architecture behind the allocation

The US institutional funds deploying into Israel are themselves funded substantially by US public pensions, university endowments, foundations, family offices, and sovereign-adjacent vehicles. The LP base includes:

• Major US public pension systems — CalPERS, CalSTRS, NY Common Retirement Fund, the Texas systems, and the broader state pension network.
• The major US university endowments — Harvard, Yale, Princeton, Stanford, MIT, and the broader endowment bench. Yale's exposure to Israeli VC has been particularly long-running.
• Family offices and large foundations — including Jewish family offices and foundations with explicit Israel-allocation mandates, as well as non-Jewish foundations with broader international VC exposure.
• Sovereign-adjacent vehicles — Saudi PIF (selectively, through US-anchored funds), GIC, Temasek, and the broader sovereign LP bench.

The Israeli allocation is therefore a layered architecture: US institutional LPs to US VC funds to Israeli portfolio companies. The chain runs in dollars, on US legal documentation, with US fund partners managing the relationship.

The shape of the post-2022 allocation

The reset that began in mid-2022 compressed US VC deployment into Israel by approximately the same magnitude it compressed deployment in the United States itself — call it 50-60% peak-to-trough through 2023, with partial 2024-2025 recovery and 2026 stabilization.

The composition shifted with the volume. The early-stage Israeli rounds shifted toward more Israel-anchored capital — Pitango, Aleph, Glilot, NFX, Team8 — and away from US-led seeds and Series A's. The growth-stage Israeli rounds, in contrast, remained dominantly US-led, with Bessemer, Insight, and Sequoia continuing to anchor the late-stage book.

This bifurcation matters for founders. A 2026 Israeli company raising a $20 million Series A is more likely to do so with an Israeli lead. The same company raising a $150 million Series C is overwhelmingly likely to do so with a US lead. The funds with the institutional capital base for late-stage Israeli growth rounds remain dominantly US-headquartered.

The October 7 effect

The post-October 7 risk-premium expansion did not pull US institutional VC out of Israel in any material way. The major US-anchored funds maintained pace and deployment. The visible effect was structural rather than tactical: a higher discount rate applied to Israeli valuations, more emphasis on revenue and cash-generation metrics relative to growth narratives, and more attention to operating-team continuity through the reserve mobilization.

By 2026, with the security situation more stable and the broader VC environment recovered, US institutional VC allocation to Israel is running at approximately the pre-reset baseline. The structural commitment is intact. The cyclical reset has worked through.

The US institutional VC channel remains the largest single source of growth capital for the Israeli technology economy. For the foreseeable future — through institutional inertia, partner-level continuity, and LP-base structure — it will continue to be.